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Abstract
The current effectiveness of HAART in the management of HIV infection is compromised by the 
emergence of extensively cross-resistant strains of HIV-1, requiring a significant need for new 
therapeutic agents. Due to its crucial role in viral maturation and therefore HIV-1 replication and 
infectivity, the HIV-1 protease continues to be a major development target for antiretroviral therapy. 
However, new protease inhibitors must have higher thresholds to the development of resistance and 
cross-resistance. Research has demonstrated that the binding characteristics between a protease 
inhibitor and the active site of the HIV-1 protease are key factors in the development of resistance. 
More specifically, the way in which a protease inhibitor fits within the substrate consensus volume, or 
“substrate envelope”, appears to be critical. The currently available inhibitors are not only smaller than 
the native substrates, but also have a different shape. This difference in shape underlies observed patterns 
of resistance because primary drug-resistant mutations often arise at positions in the protease where 
the inhibitors protrude beyond the substrate envelope but are still in contact with the enzyme. Since 
all currently available protease inhibitors occupy a similar space (in spite of their structural differences) 
in the active site of the enzyme, the specific positions where the inhibitors protrude and contact the 
enzyme correspond to the locations where most mutations occur that give rise to multidrug-resistant 
HIV-1 strains. Detailed investigation of the structure, thermodynamics, and dynamics of the active site 
of the protease enzyme is enabling the identification of new protease inhibitors that more closely fit 
within the substrate envelope and therefore decrease the risk of drug resistance developing. The features 
of darunavir, the latest FDA-approved protease inhibitor, include its high binding affinity (Kd = 4.5 × 10
-12 M) 
for the protease active site, the presence of hydrogen bonds with the backbone, and its ability to fit 
closely within the substrate envelope (or consensus volume). Darunavir is potent against both wild-type 
and protease inhibitor-resistant viruses in vitro, including a broad range of over 4,000 clinical isolates. 
Additionally, in vitro selection studies with wild-type HIV-1 strains have shown that resistance to darunavir 
develops much more slowly and is more difficult to generate than for existing protease inhibitors. 
Clinical studies have shown that darunavir administered with low-dose ritonavir (darunavir/ritonavir) 
provides highly potent viral suppression (including significant decreases in HIV viral load in patients 
with documented protease inhibitor resistance) together with favorable tolerability. In conclusion, as 
a result of its high binding affinity for and overall fit within the active site of HIV-1 protease, darunavir 
has a higher genetic barrier to the development of resistance and better clinical efficacy against 
multidrug-resistant HIV relative to current protease inhibitors. The observed efficacy, safety and tolerability 
of darunavir in highly treatment-experienced patients makes darunavir an important new therapeutic 
option for HIV-infected patients. (AIDS Rev. 2008;10:131-42)
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Introduction
Although HAART has successfully improved the 
management of HIV infection by reducing mortality and 
slowing the progression to AIDS, its widespread ef-
fectiveness is compromised with the emergence of 
extensively cross-resistant strains of HIV-11-4. The de-
gree of cross-resistance to different drugs within a 
drug class has been shown to vary according to the 
number and type of mutations5. The transmission of 
drug-resistant HIV is also a growing problem, with 5-25% 
of newly infected individuals being infected with resis-
tant virus6-9. Despite the use of HAART, incomplete 
viral suppression and persistent low-level viremia can 
be associated with the development of clinically sig-
nificant resistance and poor long-term clinical outcome, 
even when overt virologic failure is not apparent10-12. 
For protease inhibitors (PIs), Richman, et al. estimated 
that 41% of patients with HIV viral load > 500 copies/
ml were resistant to one or more of the drugs in the 
class3. 
Nevertheless, despite the challenges of potential 
drug resistance, HIV protease continues to be a prime 
target for antiretroviral therapy because of its essential 
role in viral replication13,14. Nine HIV-1 PIs have been 
approved by the U.S. Food and Drug Association 
(FDA): amprenavir, atazanavir, indinavir, lopinavir, nel-
finavir, ritonavir, saquinavir, tipranavir, and recently 
darunavir (previously TMC114). To be effective, a PI 
should combine the following characteristics: improved 
binding to the protease, prevention of the development 
of resistance, high potency against both wild-type and 
resistant HIV strains, effective and durable virologic 
suppression, favorable tolerability, and convenience. 
This article profiles the balance of substrate recognition 
and reviews the existing HIV-1 PIs, including tipranavir, 
in comparison with the unique in vitro and clinical prop-
erties of the latest FDA-approved PI, darunavir15-17.
The structural and dynamic determinants 
of substrate recognition in HIV-1 protease
During virion maturation, HIV-1 protease specifically 
cleaves the posttranslational precursor polyproteins 
Gag and Gag-Pro-Pol in at least nine nonhomologous 
sites, releasing six structural proteins (matrix, capsid, 
p2, nucleocapsid, p1, and p6) and four enzymes (pro-
tease, reverse transcriptase, RNaseH, and integrase)18. 
This processing is essential for viral maturation and 
therefore HIV-1 replication and infectivity. Abolition of 
protease activity by either deletions or point mutations 
results in the production of noninfectious viral parti-
cles13,19. The HIV-1 protease’s extreme specificity and 
critical role in viral maturation makes it an attractive 
target for antiretroviral drugs13,14. 
The HIV-1 protease is a small aspartyl protease. Like 
other retroviral aspartyl proteases20,21 it is active as a 
symmetric homodimer, but each monomer is only 
99 amino acids long. The structure is primarily β-sheet 
with the active site at the dimer interface. Each mono-
mer contributes one critical aspartic acid22 to form the 
active enzyme. The dynamics of HIV-1 protease are 
also critical to function, as the substrate sites within the 
Gag and Gag-Pro-Pol polyproteins access the active 
site when two large flexible flaps open23-25 then close 
over the active site allowing proteolysis of the substrate 
to occur. The flaps then reopen and allow the cleaved 
products to be released. 
The substrate sequences that HIV-1 protease 
cleaves are diverse in sequence and asymmetric; 
however, it is not a promiscuous enzyme, but rather is 
highly specific. The rate and order in which the se-
quences are cleaved is site-specific. Crystal struc-
tures of peptide complexes have been determined 
that correspond to the various cleavage sites in Gag 
and Gag-Pro-Pol26-33. Analysis of the structures of the 
substrate complexes revealed that although the se-
quen ces are diverse, the structures that they form 
pack into a conserved asymmetric shape31. This asym-
metric shape appears to determine the enzyme’s spe-
cificity rather than any particular amino acid sequence 
or hydrogen bonding pattern30,31. The conservation of 
this shape was determined by the intersection of the 
van der Waals sur faces of the substrates, and this in-
ter secting volume or consensus volume has been de-
fined as the protease “substrate envelope”, or the 
region within the active site that is most critical for 
substrate recognition (Fig. 1)15,34.
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Characterization of protease inhibitors 
– structures and thermodynamics
The HIV PIs were the first success of structure-based 
drug design22. All of the clinically successful ones are 
competitive active-site inhibitors. They interact with 
the active site in such a way as to keep the flaps of the 
en zyme tightly closed over the active site, thus mimick-
ing the transition state and thereby effectively inactivating 
the enzyme. Most of the inhibitors, even those who se 
precursors were found through screening libraries, 
were optimized with successive co-crystal crystal 
structures35-41.
Chemically, these inhibitors have generally hydro-
phobic moieties that interact with the mainly hydropho-
bic S2-S2’ pockets in the active site. Structurally, there 
are two types of HIV PI: peptidomimetic PI, which com-
prise the majority of approved PIs including darunavir, 
and non-peptidomimetic PI such as tipranavir41. 
In addition to structure, isothermal titration calorim-
etry has been extensively utilized to characterize the 
thermodynamics of the binding of these inhibitors to 
HIV-1 protease34,42-47. Under specified temperature 
and buffer conditions, thermodynamics allows for the 
enthalpy and entropy of a molecular interaction to be 
characterized. The inhibitors vary in binding affinity 
from nanomolar to picomolar. However, to achieve 
these binding affinities there are a wide variety of dif-
ferent combinations of more favorable entropy or en-
thalpy. Many of the first-generation inhibitors, despite 
being designed on the basis of structural interactions, 
are actually enthalpically unfavorable and are driven 
into the active site by the entropically favorable action 
of burial of relatively rigid hydrophobic groups. Recent 
theories suggest that enthalpically driven inhibitors 
may be more resilient to resistant variants of HIV-1 
pro tease34,46; however, whether this is universal re-
mains to be verified.
Recently approved protease inhibitors
The most recently approved PI, darunavir, is a pep-
tidomimetic PI, containing a 3(R), 3a(S), 6a(R)-bis-tet-
rahydrofuranylurethane (bis-THF) group. Darunavir is 
highly potent in vitro and in vivo against a broad range 
of HIV-1 strains, including wild-type virus and a variety of 
multidrug-resistant (MDR) clinical strains15,27,48-51. Da-
ru navir was identified in a unique research and devel-
opment program, which assessed potential PI com-
pounds by profiling their antiviral activity against a 
pa nel of recombinant HIV strains derived from highly 
PI-resistant and cross-resistant clinical isolates. Addi-
tionally, several thousand clinical isolates with varying 
degrees of PI resistance were also used for the evalu-
Figure 1. Substrate envelope of HIV protease. GRASP model generated from overlapping van der Waals volume of substrate peptides. 
Red: matrix capsid; green: capsid-p2; blue: p2-nucleocapsid; cyan: p1-p6; magenta: reverse transcriptase-ribonuclease H; yellow: ribonu-
clease H-integrase (reprinted from Chemistry & Biology, Vol. 11, Nancy M King, Moses Prabu-Jeyabalan, Ellen A Nalivaika, and Celia Schiffer, 
Combating susceptibility to drug resistance: lessons from HIV-1 protease, p1333-8, Copyright 2004, with permission from Elsevier34).
P4 P2 P1’ P3’
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ation of the most interesting compounds16,51. Two key 
evaluation criteria were high potency against both wild-
type and MDR HIV-1 strains, and a favorable pharma-
cokinetic profile following oral administration. From this 
search, the prototype compound TMC126 was identi-
fied. To improve the pharmacokinetic profile of TMC126 
while retaining its high potency, a series of closely re-
la ted compounds, all of which had the bis-THF moiety 
for improved interaction in the P2-pocket, were synthe-
sized and darunavir was identified as the lead com-
pound for clinical development (Fig. 2).
Although darunavir has some chemical similarities to 
amprenavir, it binds approximately 100-times more 
tightly to wild-type protease (Kd = 4.5 × 10
–12 M vs. Kd 
= 3.9 × 10–10 M) and 1,000-times more tightly than in-
dinavir, nelfinavir, ritonavir, and saquinavir15,52. The 
unique high binding affinity of darunavir may partly be 
due to the bis-THF moiety at P2’17. This moiety forms 
strong hydrogen bonds with the backbone atoms of 
re sidues D29 and D30. These hydrogen bonds may be 
par tially responsible for the very favorable binding en-
thalpy of darunavir to the wild-type protease (–12.1 kcal/
mol)16 and very slow dissociation rate52. Together with 
further hydrogen bonds between darunavir and the 
backbone atoms at the base of the active site, the drug 
mimics the conserved hydrogen bonds of the natural 
substrates30,31. In contrast, other PIs form more exten-
sive interactions with the protease side-chains48,49.
Tipranavir is another recently approved PI. Tiprana-
vir is non-peptidomimetic (sulfonamide-containing 
5,6-dihydro-4-hydroxy-2-pyrone) and as such is struc-
turally unrelated to the other PIs53. Identified through 
structure-based drug design, tipranavir is a potent 
inhibitor of the HIV-1 protease with a dissociation con-
stant for inhi bitor binding of Kd = 1.9 × 10
–11 M54. A 
study examin ing the thermodynamic basis of the po-
tent antiviral activity of tipranavir against PI-resistant 
mutants found that in contrast to darunavir, the high 
potency of tipra na vir results from a large entropy 
change (−14.6 kcal/mol) combined with a small en-
thalpy change (−0.7 kcal/mol)54. The structure of tip-
ranavir allows seven direct hydrogen bonds to be 
established with conserved re sidues of the protease 
enzyme, and makes fewer water-mediated hydrogen 
bonds compared with other PIs. Together with the 
retention of structural flexibility, these features allow 
enthalpy interactions to compensate for conforma-
tional entropy losses induced in the presence of re-
sistance mutations. This is also thought to go some 
way towards explaining the activity of tipranavir 
against resistant viruses54. 
Protease inhibitor resistance  
and cross-resistance
In general, drug resistance occurs when mutations 
in the target protein enable it to retain function while 
no longer being effectively inhibited by the drug34. The 
high viral replication rate combined with the highly 
error-prone reverse transcriptase and the selective 
pressure of therapy cause many drug-resistant mutants 
of HIV-1 to emerge43,55,56. Since the introduction of PIs, 
drug-resistant mutations in the protease have become 
widespread. These mutations render the variant pro-
tease resistant to the inhibitor, while allowing it to main-
tain its function in cleaving its natural substrates5,34. 
Mutations in at least 34 of the 99 residues of HIV-1 
pro tease have been found to have clinical signifi-
cance56-59. Although only a subset of these mutations 
(e.g. D30N, G48V, V82A, I84V, I50V, and I50L) affect 
inhibitor binding by an alteration of a direct point of 
contact within the active site, many others alter inhibitor 
binding by altering the balance between substrate rec-
ognition and inhibitor binding. The HIV-1 found in most 
highly PI-experienced patients has between 5-15 muta-
tions in the protease gene56,57. These are often in spe-
cific combinations of mutations both inside and outside 
the active site. Mutations outside the active site may 
not only impact inhibitor binding, but also compensate 
for the viability and fitness of the enzyme and thus 
increase the growth rate of the mutant virus60,61. 
Varying degrees of resistance to all of the PIs have 
been described and cross-resistance among the old-
er PIs is common5,62,63. In a phenotypic and geno-
typic analysis of antiretroviral drug resistance to indi-
navir, nelfinavir, ritonavir, and saquinavir in more than 
6,000 pa tient isolates from Europe and the USA, phe-
notypic resistance to any single PI was found in 17-25% 
of iso lates. Cross-resistance was found in 59-80% of 
those isolates that were resistant (greater than 10-fold 
increase in inhibitory concentration [EC50]) to at least 
one PI62. Although certain predominantly primary ac-
tive-site mutations are closely associated with a par-
ticular PI64,65, such as D30N with nelfinavir, G48V with 
saquinavir, I50V with amprenavir, or I50L with atazana-
vir, others such as V82A and I84V impact almost all of 
the PIs. The active-site mutations are often combined 
with other common mutational patterns that contribute 
to PI cross-resistance, including combinations of muta-
tions at L10I, I54V or T, A71V or T, V77I, and L90M56,57,62. 
The structural similarities between darunavir and am-
prenavir may contribute to some shared determinants 
of resistance. Recent studies have indicated that 
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previous use of or resistance to (fos)amprenavir may 
be associated with a higher level of resistance to 
darunavir66,67, although in phase IIb trials the impact 
on virologic response to darunavir was minimal68. This 
commonality potentially limits the success of subse-
quent therapy following virologic failure of PI-containing 
regimens, since fewer new mutations may be required 
to produce viruses that are clinically resistant to the 
PI(s) in the salvage regimen69. 
Why is there so much cross-resistance between the 
PIs? Although there are clear chemical differences 
between all the currently available PI, when bound in 
the active site of HIV-1 protease they occupy a similar 
space and even have similar functional groups at 
similar positions (Fig. 3). As a result, atoms of different 
PIs frequently come into contact with the protease at 
the same residues34. Thus, mutations at these residues 
in HIV-1 protease produce MDR viruses15,34,70. The key 
mo lecular recognition question is how do the protease 
variants, with resistance mutations in their active sites 
that confer resistance to competitive inhibitors, retain 
the ability to recognize and cleave substrates and thus 
maintain viable virus? This retention of activity often 
occurs without co-evolution of the substrate sequences. 
A partial answer to this puzzle was found when the 
inhibitor complexes were superimposed on the substrate 
complexes32,34 (Fig. 4). Not only are the inhibitors 
smaller than the substrates, but they also have a different 
shape than the substrates. The superimposition studies 
found that drug resistance mutations occur at positions 
where the inhibitors protrude beyond the substrate 
consensus volume (or substrate envelope) but are still 
in contact with the enzyme. This explains how resistance 
can occur without having a significant impact on func-
tion, as those residues are more important to inhibitor 
binding than they are for substrate recognition and 
thus are prime locations for resistant mutations.
Avoiding cross-resistance  
among protease inhibitors
For a PI to maintain effectiveness against resistance 
mutations, two characteristics are required: a high binding 
affinity for the wild-type protease, and resilien ce to the 
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Figure 2. Chemical structure of darunavir (TMC114) and TMC126 (reproduced with permission15).
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to drug resistance, as any mutation that affects the 
inhibitor would simultaneously affect the recognition of 
a substantial proportion of the substrates. 
In fact, darunavir and amprenavir more closely mimic 
substrate interactions because they fit within the sub-
strate consensus volume or substrate envelope better 
than any of the other PIs (Fig. 5)15,34. The combination 
of tight binding, mimicking substrate hydrogen bonds, 
and the overall fit within the substrate envelope should 
provide darunavir with a higher “genetic barrier” to the 
development of resistance, as the backbone interac-
tions are not changed by mutation. Furthermore, the 
mutations that perturb darunavir binding will have a 
negative impact on substrate recognition and cleavage, 
and are either less likely to occur or will result in reduced 
viral replication. Thus, based on simple molecular inter-
action principles, this suggests that darunavir should 
have greater robustness in treating HIV-1 infection. 
This strength was demonstrated when comparing the 
binding of darunavir to wild-type protease with binding 
to a prototype MDR HIV-1 protease variant (I84V, V82T). 
Variant I84V is the most common resistance mutation 
that affects the binding of every currently used PI. The 
flexible N-isobutyl group of darunavir interacts with 
residue 84 (Fig. 5) in the protease active site and al-
lows for conformational adjustments in the ligand and 
possible retention of binding affinity. However, the 
binding affinity of darunavir (measured by isothermal 
titration calorimetry) was reduced by a factor of 13.3. 
Nevertheless, despite the reduction in binding affinity 
to this variant HIV protease, darunavir still binds with a 
60 pM binding affinity which is more than 33-fold high-
er than amprenavir and more than 1.5 orders of mag-
nitude higher than older PIs15. Other recent studies 
have examined the structure and binding affinity with 
other resistant variants27,50 and found a maximum of 
30-fold loss in binding affinity to the I50V variant, a 
known amprenavir-resistant mutation and a point of 
contact outside of the substrate envelope (Fig. 5). 
Thus, the high binding affinity of darunavir appears to 
provide re silience against the effect of resistance mu-
tations in the HIV-1 protease at the molecular level.
Activity of darunavir against  
wild-type and resistant strains of HIV,  
and development of resistance in vitro
Darunavir has demonstrated strong potency against 
both wild-type and PI-resistant viruses in vitro, including 
a broad range of over 4,000 clinical isolates48,51. In vitro, 
darunavir showed potent activity against wild-type HIV-1 
Figure 3. The inhibitor envelope in red, as it fits within the active site 
of HIV-1 protease, calculated from overlapping van der Waals vol-
ume of five or more of eight inhibitor complexes. The colors of the 
inhibitors are yellow: nelfinavir; gray: saquinavir; cyan: indinavir; light 
blue: ritonavir; green: amprenavir; magenta: lopinavir; blue: atazanavir; 
red: darunavir (reprinted from Chemistry & Biology, Vol. 11, Nancy M 
King, Moses Prabu-Jeyabalan, Ellen A Nalivaika, and Celia Schiffer, 
Combating susceptibility to drug resistance: lessons from HIV-1 pro-
tease, p1333-8, Copyright 2004, with permission from Elsevier34).
P2 P1’
P3 P1 P2’
effect of mutations; i.e. the PI is able to main tain viable 
binding affinity and effective inhibition in the presence of 
those mutations32,34,71. The traditional approach to com-
bating drug resistance has included the characterization 
and targeting of each drug-resistant variant protein to 
enable the identification of new active inhibitors72,73. How-
ever, this is not practical for HIV-1 protease as more than 
one-third of the 99 residues are known to mutate and 
contribute in various combinations to PI resistance56,57. 
We have proposed a general strategy of structure-based 
design to decrease the probability of drug resistance 
developing, by designing inhibitors that interact only with 
those residues that are essential for function34. For HIV-1 
protease, this would mean developing a PI that is con-
tained within the substrate envelope and thus interacts 
only with the same residues that are required for substrate 
recognition. Such an inhibitor would be less susceptible 
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Figure 4. Superimposition of the substrate consensus volume (blue) with the inhibitor consensus volume (red). Residues that contact with 
the inhibitors where the inhibitors extend beyond the substrate volume and confer drug resistance when they mutate are labeled (reprinted 
from Chemistry & Biology, Vol. 11, Nancy M King, Moses Prabu-Jeyabalan, Ellen A Nalivaika, and Celia Schiffer, Combating susceptibility 
to drug resistance: lessons from HIV-1 protease, p1333-8, Copyright 2004, with permission from Elsevier34).
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Figure 5. Crystal structure of darunavir superimposed on the structure of the substrate envelope derived from the substrate crystal struc-
tures. Atoms that protrude from the envelope are shown in red and labeled. Other labels highlight protease residues within van der Waals 
contact of the protruding atoms (reproduced with permission15).
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and HIV-2, with an EC50 of 1-5 nM and an EC90 of 2.7-
13 nM, with no observed cytotoxicity at concentrations 
up to 100 μM51. Darunavir also demonstrated good activ-
ity against 19 recombinant clinical isolates, with multiple 
protease mutations and phenotypic resistance to an av-
erage of five PIs. Except for one strain, darunavir showed 
EC50 of < 10 nM for all isolates compared with EC50 of 
> 100 nM for nelfinavir, indinavir, ritonavir, amprenavir, 
saquinavir, and lopinavir. Against 1,501 clinical isolates 
with a fourfold or greater change in EC50 for one or more 
PIs, darunavir inhibited 75% of viruses with an EC50 of 
< 10 nM and 21% of viruses with an EC50 of 10-100 nM. 
Darunavir was more potent against these PI-resistant 
strains than any other PI tested (amprenavir, indinavir, 
lopinavir, nelfinavir, ritonavir, and saquinavir)48.
Koh, et al. also demonstrated that darunavir has 
potent in vitro activity against wild-type HIV-1 and HIV-
2 and MDR clinical HIV-1 strains48. Compared with 
amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and 
saquinavir, which suppressed the infectivity and repli-
cation of HIV-1 LAI with EC50 of 17-47 nM, darunavir 
showed superior potency (EC50 3 nM). Darunavir also 
showed potent activity against HIV-1 Ba-L (EC50 3 nM) 
and two HIV-2 strains (EC50 3-6 nM), activity that was 
greater than that of the other PIs tested. 
Preliminary data from in vitro selection studies with 
wild-type HIV-1 strains have shown that resistance to 
darunavir develops much slower and is more difficult 
to generate than for existing PIs16,51. De Meyer, et al. 
showed that selection of resistant HIV with amprenavir, 
lopinavir, and nelfinavir was more rapid and easier than 
with darunavir, and resulted in the emergence of strains 
carrying clinically relevant PI resistance-associated 
mutations (Fig. 6)16,51. The concentrations of these PI 
could readily be increased to > 1 μM and still allow 
vi rus replication. In contrast, the concentration of daru-
navir could not be increased rapidly and virus replica-
tion did not occur at concentrations > 200 nM (Fig. 6). 
Moreover, the mutations emerging in the selected strains 
(R41T and K70E) have never been associated with re-
sistance to PI, and when introduced in a wild-type 
genetic background by site-directed mutagenesis, did 
not cause decreased susceptibility to darunavir71.
Clinical activity
In clinical studies, darunavir is administered together 
with low-dose ritonavir (darunavir/ritonavir). Published 
results from one phase IIa clinical study and two phase 
IIb studies indicate that darunavir/ritonavir has potent 
antiviral activity in PI-experienced patients75-77. In the 
24-week, dose-finding portion of two large, randomized, 
controlled, 144-week phase IIb studies (POWER 1 
[TMC114-C213] and POWER 2 [TMC114-C202]), pa-
tients were nucleoside reverse transcriptase inhibitor 
(NRTI)-experienced, nonnucleoside reverse transcriptase 
inhibitor (NNRTI)-experienced, and PI-experien ced, 
had at least one primary PI mutation (according to the 
IAS-USA guidelines) and had viral load ≥ 1,000 co pies/ml 
at screening76,77. Both studies were of similar design. 
Patients were randomized to receive either in ves tigator-
selected PI(s) or one of four darunavir/ritona vir doses: 
400/100 mg 1/d, 800/100 mg 1/d, 400/100 mg 2/d, or 
600/100 mg 2/d; all regimens were given in combina-
tion with an optimized background regimen (OBR: at 
least two NRTIs with or without enfuvirtide). Patients 
were stratified by the number of primary PI mu tations, 
by the use of enfuvirtide, and by screening viral load. 
The primary endpoint was the proportion of patients 
with a decrease in viral load of ≥ 1 log10 HIV RNA cop-
ies/ml at week 24. Secondary endpoints included the 
decrease in viral load from baseline, the proportion of 
patients with HIV RNA < 50 copies/ml, and the mean 
change in CD4 cell count at week 24.
The baseline characteristics showed that patients in 
the POWER 2 study had somewhat more advanced 
disease (longer duration of infection, lower baseline 
CD4 and higher viral load), more patients had virus 
resistant to all commercially available PIs (71 vs. 63%), 
and a greater percentage of patients had three or more 
primary PI mutations (66 vs. 56%) than in the POWER 
1 study77. In both studies, darunavir/ritonavir plus OBR 
was shown to be significantly more effective than in-
vestigator-selected PI(s) plus OBR for both suppres-
sion of HIV-1 RNA and increase in CD4 cell count. 
In the POWER 1 study, 77% of patients receiving 
darunavir/ritonavir 600/100 mg 2/d (the dose selected 
for further development in treatment-experienced pa-
tients) achieved at least a 1.0 log10 reduction in viral 
load relative to baseline, compared with only 25% of 
control patients (p < 0.001)76. Similarly, significantly more 
darunavir/ritonavir patients had viral load < 50 co pies/ml 
at week 24 compared with control patients (53 vs. 18%; 
p < 0.001). Increases in mean CD4 cell count were 
substantially greater at week 24 versus baseline for 
darunavir/ritonavir compared with the control group 
(124 vs. 20 cells/mm3; p < 0.001). 
Similar results were observed in the POWER 2 study, 
which recruited more advanced patients; significantly 
more patients on darunavir/ritonavir 600/100 mg 2/d 
achieved at least a 1.0 log10 reduction in viral load re-
lative to baseline compared with control patients (62 vs. 
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14%; p < 0.001)77. Patients on the recommended dose 
of darunavir/ritonavir were also more likely to achieve a 
viral load < 50 copies/ml than control patients (39 vs. 
7%; p < 0.001). The mean increase in CD4 cell count 
at week 24 versus baseline was significantly greater for 
patients on darunavir/ritonavir 600/100 mg compared 
with control patients (59 vs. 12 cells/mm3; p < 0.01). 
At week 24, the overall mean changes versus base-
line in log10 viral load (NC = F) for the darunavir/ritona-
vir 600/100 mg 2/d treatment groups of the POWER 1 
and 2 studies were –2.03 and –1.71 copies/ml, respec-
tively76,77. In the control groups, the mean changes 
versus baseline in log10 viral load were –0.63 and 
–0.29 co pies/ml, respectively76,77. Importantly, the 
magnitude of the differences in change in viral load 
between the da runavir/ritonavir 600/100 mg 2/d groups 
and the con trol groups of the POWER 1 and 2 studies 
were comparable: a difference of 1.35 and 1.37 cop-
ies/ml, respectively76,77. 
Subgroup analyses demonstrated that the inclusion 
of a greater number of active antiretrovirals (including 
NRTI and enfuvirtide) in the OBR was associated with 
better virologic outcomes in all treatment groups. In the 
POWER 1 study, 63% of patients receiving darunavir/
ritonavir 600/100 mg 2/d and using enfuvirtide for the 
first time achieved suppression < 50 copies/ml at week 
24 compared to 56% of patients who did not receive 
enfuvirtide (for control: 22 and 19%, respectively)76. In 
the POWER 2 study, this was 64 and 30% of patients, 
respectively (for control: 7 and 4%, respectively)77. This 
apparent difference was likely related to the number of 
other viable agents in their OBR. On the recommended 
dose, the population evaluated in the POWER 1 study 
had a greater proportion of patients with one or more 
susceptible NRTIs than POWER 2 (77 vs. 62%)76,77. 
Ta ken together, these findings underscore the value of 
using at least two potent antiretroviral agents in heav-
ily treatment-experienced patients. Similar results were 
obtained with a comparable patient population receiving 
the darunavir/ritonavir 600/100 mg 2/d dose, in a non-
randomized integrated analysis of two trials (POWER 3 
[TMC114-C215 and C208])78. 
The pooled POWER 1 and 2 48-week analysis sho wed 
darunavir/ritonavir provided durable efficacy in this 
highly treatment-experienced population79. More re-
cently, treatment with darunavir/ritonavir 600/100 mg 
2/d was shown to be statistically non-inferior and superior 
to lopinavir/ritonavir 400/100 mg 2/d for the endpoint 
of viral load < 400 copies/ml in early treatment-ex-
perienced patients at 48 weeks in the phase III TI TAN 
trial80. Treatment with darunavir/ritonavir 800/100 mg 
1/d in treatment-naive patients was also shown to be 
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Figure 6. In vitro selection of resistant HIV from wild-type in the presence of amprenavir, lopinavir, nelfinavir, or darunavir (TMC114) in 
sequential passage experiments. Each passage represents 3-4 days, with passage 75 representing a total of 260 days. Enlarged symbols 
indicate genotypes of viruses selected at defined times and list all genotypic changes from the original HIV-1 LAI strain. Curves are normal-
ized and starting concentrations were 10, 20, 100, and 100 nM for darunavir (TMC114), lopinavir, amprenavir, and nelfinavir, respectively 
(reproduced with permission51). APV: amprenavir; NFV: nelfinavir; LPV: lopinavir: TMC114: darunavir.
AIDS Reviews. 2008;10
140
non-inferior to lopinavir/ritonavir 800/200 mg (either 1/d 
or 400/100 mg 2/d) for the endpoint of viral load < 50 
co pies/ml in the phase III ARTEMIS trial at 48 weeks, 
and was more effective in patients with baseline HIV-1 
RNA above 100,000 copies/ml81.
In terms of safety, darunavir showed no cytotoxicity 
at concentrations of up to 100 μM in in vitro studies51. 
In patients, darunavir/ritonavir has been shown to be 
well tolerated in a phase IIa clinical study and the pha-
se IIb POWER 1 and POWER 2 controlled studies75-77. 
In a combined analysis of all darunavir/ritonavir dose 
groups from POWER 1 and POWER 2, the most com-
mon adverse events (occurring in ≥ 10% of patients, 
regardless of severity and causality) were similar in 
da runavir/ritonavir-treated patients and in the control 
arms; in decreasing order of incidence, these were: 
diarrhea, headache, nausea, fatigue, nasopharyngitis, 
upper respiratory tract infection, insomnia, cough, her-
pes simplex, and pyrexia82. The combined safety anal-
ysis revealed that there were more discontinuations in 
the control group (81% total: 67% for virologic failure, 
5% for adverse events) than in the darunavir/ritonavir 
groups (25% total: 12% for virologic failure, 8% for ad-
verse events) resulting in a shorter treatment duration 
for control patients. Finally, the safety results of the 
POWER 1 and POWER 2 studies showed no apparent 
re lationship between darunavir dose and adverse 
event incidence, and no overall difference compared 
to PI used in the control groups. The safety results of 
POWER 3 were similar to those of POWER 1 and POW-
ER 278. The pooled 48-week analysis of POWER 1 and 
2 safety and tolerability results79, along with the more 
re cent 48-week data from the two phase III TITAN80 
and ARTEMIS81 trials, confirmed the favorable tolerabil-
ity of darunavir/ritonavir treatment.
Darunavir/ritonavir can be used in patients with mild 
to moderate liver impairment. However, increased 
aspartate and alanine aminotransferase monitoring 
should be considered in patients with underlying 
chronic hepatitis, cirrhosis, or in patients who have 
pretreatment elevations of transaminases, especially 
during the first several months of treatment.
Darunavir resistance in the clinic
The most predictive factor for virologic outcome in 
the POWER 1, 2, and 3 studies was the fold change in 
EC50 value for darunavir at baseline. The determinants 
of increased fold change for darunavir were researched 
by analyzing the influence of both the number and the 
type of protease mutations on the virologic response 
at week 24, as well as the mutations that emerged 
upon virologic failure while on darunavir treatment. 
Mutations present at study baseline that were associ-
ated with a diminished virologic response to darunavir/
ritonavir were V11I, V32I, L33F, I47V, I50V, I54L/M, 
G73S, L76V, I84V, and L89V. Isolates from patients 
harboring these mutations tended to have a higher 
number of PI resistance-associated mutations, as com-
pared with patients who did not harbor these mutations 
at baseline. Even in the presence of these mutations, 
however, virologic response in the darunavir/ritonavir 
arm was higher than for the control arm. 
Mutations that developed on-study in ≥ 10% of patients 
who failed virologically were V32I, L33F, I47V, I54L, 
and L89V. However, when introduced in a wild-type 
genetic background by site-directed mutagenesis, mu-
tations V32I, L33F, I47V, or I54L (alone or in combina-
tion with one or two other PI resistance-associated 
mutations) did not cause decreased susceptibility to 
darunavir (mutation L89V is currently being studied). 
In terestingly, darunavir makes contacts outside of the 
substrate envelope at V32, I47, I50, and I84 (Fig. 5) 
making several of these sites of mutation consistent 
with the substrate envelope theory. Finally, isolates 
from patients experiencing virologic failure by rebound 
showed a median 8.14-fold change increase for daru-
navir at endpoint compared with baseline. In the same 
group of patients, however, no such fold change 
increa se (median increase of 0.82) was found for tip-
ranavir, suggesting limited cross-resistance between 
these two PI. However, this is based on a small number 
of obser vations. The fold change increase could not 
be studied for the other PIs, since the baseline isolates 
were alrea dy resistant to these PIs. 
Thus, mutations developing upon virologic failure in 
this population of highly treatment-experienced pa-
tients with extensive PI resistance conferred resistance 
to darunavir only in the presence of a high number of 
PI resistance-associated mutations83. 
Conclusions
As resistance continues to be a problem with the 
currently available antiretrovirals, there is a significant 
need for new agents. In the case of PIs, these must 
have a higher threshold to the development of resistance. 
This should help limit the development of cross-resis-
tance. The binding characteristics between a PI and 
the active site of the HIV-1 protease have been shown to 
be important factors in the development of resistance 
and cross-resistance. In particular, how PIs fit within 
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the substrate envelope (or substrate consensus volume) 
seems to be crucial, since primary drug-resistant muta-
tions frequently occur at positions in the protease that 
are contacted by PI atoms that protrude beyond it. In 
addition, these specific residues correspond to those 
where most MDR mutations occur. Insight into the 
structure, thermodynamics, and dynamics of the active 
site should enable the design of new PIs that mostly fit 
within the substrate envelope and thus reduce the po-
tential for the development of drug resistance. 
Darunavir is a novel PI with improved potency and 
binding characteristics compared with most currently 
available PIs. Important distinguishing features include 
high binding affinity for the protease binding site, the 
presence of hydrogen bonds with the backbone at 
the active-site cleft, and fitting primarily within the sub-
strate envelope or substrate consensus volume. Daru-
navir/ritonavir has demonstrated potent in vitro activity 
against wild-type and PI-resistant viruses and proves 
difficult to select for resistance in vitro. In clinical studies, 
darunavir/ritonavir has demonstrated highly potent viral 
suppression, including highly significant decreases in 
HIV viral load in both treatment-naive and treatment-
experienced patients with documented PI resistance, 
favorable tolerability, and the potential for both twice-
daily and once-daily dosing. Due to its high binding 
affinity for and the closeness and flexibility of fit within 
the protease, darunavir has a higher genetic barrier 
to the development of resistance and improved clinical 
efficacy against MDR HIV compared with most current 
PIs, making it a valuable option for the treatment of 
HIV-infected patients.
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